Risk Factors for Hormonal Therapy Failure in Patients With Endometriosis.
ConditionEndometriosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorUniversity of Cagliari
About this trial
The primary objective of our study is to determine the percentage of patients with endometriosis who are non-responsive to medical therapy after 12 months and to compare the clinical and ultrasound characteristics of this group of patients (study group) with the clinical and ultrasound characteristics of patients who are responsive to medical therapy (control group).
The secondary objective of the study will be to determine the percentage of patients with endometriosis who are non-responsive to medical therapy after 6 months and to compare the clinical and ultrasound characteristics of this group of patients (study group) with the clinical and ultrasound characteristics of patients who are responsive to medical therapy (control group).
Eligibility criteria
Qualifiers
Age between 18 and 50 years;
Patients with painful symptoms related to endometriosis (dyspareunia, dyschezia, dysmenorrhea, chronic pelvic pain, dysuria, periovulatory pain, with at least one of these symptoms presenting a Numerical Pain Rating Scale intensity > 5);
Indication for the administration of oral hormonal medical therapy for endometriosis;
Acquisition of informed consent.
Disqualifiers
Patients with contraindications to oral hormonal therapy;
Current or past pelvic infections;
History of malignancy or current suspicion of malignant gynecological lesions;
Previous pelvic surgery (hysterectomy, salpingectomy, ovarian cyst removal, myomectomy, surgery for endometriosis, intestinal resections);
Trial design
Treatments tested in this trial
- Hormonal Therapy Agent
Treatment groups
247 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov